May 23 |
Immix Biopharma Insiders Placed Bullish Bets Worth US$625.7k
|
May 10 |
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
|
Apr 29 |
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
|
Apr 18 |
Immix Biopharma on Track to Dose NXC-201 Patients in United States
|
Apr 15 |
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|